Chemotherapy of hormone-resistent cancer of the prostate


Cite item

Full Text

Abstract

A total of 59 patients with hormone-resistent prostatic cancer (HDPC) treated in 1999-2004 entered the trial. Three schemes of first-line chemotherapy were examined for clinical efficacy and toxicity in the above patients. Anticancer combined treatment vinorelbin + cycloplatam was given to 23 patients, mitoxantron + prednisolone - to 23 patients, mitoxantron+cysplatin+prednisolone - to 13 patients. The latter scheme was most effect and toxic. Partial regression of metastases and a 50% decrease in the initial PCA level were seen in 23% cases. Vinorelbin+cycloplatam was less effective and toxic: partial regression of metastases - 13%, PSA regression - 17.4%. The least efficacy and toxicity were observed in the treatment with mitoxantron+prednisolone - 8.7%. Thus, the above first-line HDPC therapy was most effective but has the highest toxicity in using the scheme mitoxantron+cysplatin+prednisolone.

References

  1. Давыдов М. И., Аксель Е. М. Злокачественные новообразования в России и странах СНГ в 2001 г. 2003. 7-10; 100- 102.
  2. Матвеев Б. П. Клиническая онкоурология. М 2003 435- 601.
  3. Joseph A., Smith J., Soloway M. S. et al. Complications of advanced prostate cancer. Urology 1999; 54 (suppl. 6A): 8-14.
  4. Rosendahl I., Kiebert G. M., Curran D. et al. Quality-adjusted survival (Q-TWIST) analysis of EORTC trial 30853. Comparing goserelin acetate and flutamide with bilateral orhiectomy in patient with metastatic prostate cancer. Prostate 1999' 38 (2Y 100-109.
  5. Корякин О. Б., Свиридова Т. В. Распространенный рак предстательной железы: результаты лечения различными методами. В кн.: Пленум Правления Российского о-ва урологов. М.; 1999. 67.
  6. Petrylak D. P. Chemotherapy for the treatment of hormone-refractory prostate cancer. Eur. Urol. Suppl. 2002; 1 (2): 15-23.
  7. Hellawel G. O., Turner G. D., Davies D. E. et al. Expression of the type I insulin-like growth factor is up-regulated in primary prostate cancer and commonly persists in metastatic disease Cancer Res. 2002; 62: 2942-2950.
  8. Petrylak D. P. Chemotherapy for advanced hormone refractory prostate cancer. Urology 1999; 54 (suppl. 6A): 30-35.
  9. Yagoda A., Petrylak D. Cytotoxic chemotherapy for advanced hormone resistant prostate cancer. Cancer 1993; 71: 1098- 1109.
  10. Abrahamson P. A. Neuroendocrine differentation in prostatic carcinoma. Prostate 1999; 39 (2): 135-148.
  11. Small E. J., Vogelzang N. J. Second-line hormone therapy for advanced prostate cancer: a shifting paradigm. J. Clin. Oncol. 1997; 15: 382-388.
  12. Eisenberger M. A., Simon R., О'Dwyer P. J. et al. A re-evaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J. Clin. Oncol. 1985; 3: 827-845.
  13. Graft N., Shostac Y., Carey M. et al. A mechanism for hormoneindependent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nature Med. 1999; 5 (3): 280-285.
  14. Green S., Furr B. Prospects for the treatment of endocrine-responsive tumors. Endocr. Relat. Cancer 1999; 6 (3): 349-371.
  15. Lein M., Yung K., Dinh L. К. et al. Synthetic inhibitor of metalloproteinases (batimastat) reduces prostate cancer growth in an orthotopic rat model. Prostate 2000; 43 (2): 77-82.
  16. Tjoa B. A., Lodge P., Salgaller M. L. et al. Dendritic-cell based immunotherapy for prostate cancer. J. Clin. Oncol. 1999; 49 (2): 117-128.
  17. Prima L. N., Meyers F. K. Treatment options in androgen-independent prostate cancer. Cancer Invest. 1999; 17 (2): 137- 144.
  18. Rosenthal M. A. Advances in the management of prostate cancer. Austral. N. Z. J. Med. 2000; 30 (5): 593-399.
  19. Beer T. M., Pierce W. C., Lowe B. A. et al. Phase II study of weekly Docetaxel (Taxotere) in hormone refractory metastatic prostate cancer. Proc. ASCO 2000; abstr. 1368.!
  20. De Mulder P., Sclken J., Sternberg C. Treatment/options in hormone resistant prostate cancer. Ann. Oncol. 2002; 13 (suppl. 4): 95-102.
  21. Logothetis С. J. Docetaxel in the integrated management of prostatae cancer - current applications and future promise. Oncology 2002; 16 (6, suppl. 6): 63-72.
  22. Tannock I. F., Osoba D., Stockier M. R. et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol. 1996; 14: 1756-1764.
  23. Kantoff P. W., Halabi S., Conoway M. et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group В 9182 study. J. Clin. Oncol. 1999; 17: 2506-2513.
  24. Жумагазин Ж. Д. Химиотерапия и иммунотерапия рака предстательной железы: Дис. ... д-ра мед. наук. 1996. 159- 173.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies